286 related articles for article (PubMed ID: 18338334)
1. The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
Lucas JM; True L; Hawley S; Matsumura M; Morrissey C; Vessella R; Nelson PS
J Pathol; 2008 Jun; 215(2):118-25. PubMed ID: 18338334
[TBL] [Abstract][Full Text] [Related]
2. Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia.
Afar DE; Vivanco I; Hubert RS; Kuo J; Chen E; Saffran DC; Raitano AB; Jakobovits A
Cancer Res; 2001 Feb; 61(4):1686-92. PubMed ID: 11245484
[TBL] [Abstract][Full Text] [Related]
3. Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer.
Chen Z; Fan Z; McNeal JE; Nolley R; Caldwell MC; Mahadevappa M; Zhang Z; Warrington JA; Stamey TA
J Urol; 2003 Apr; 169(4):1316-9. PubMed ID: 12629351
[TBL] [Abstract][Full Text] [Related]
4. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer.
Wang J; Cai Y; Ren C; Ittmann M
Cancer Res; 2006 Sep; 66(17):8347-51. PubMed ID: 16951141
[TBL] [Abstract][Full Text] [Related]
5. Down-regulated expression of prostasin in high-grade or hormone-refractory human prostate cancers.
Takahashi S; Suzuki S; Inaguma S; Ikeda Y; Cho YM; Hayashi N; Inoue T; Sugimura Y; Nishiyama N; Fujita T; Chao J; Ushijima T; Shirai T
Prostate; 2003 Feb; 54(3):187-93. PubMed ID: 12518323
[TBL] [Abstract][Full Text] [Related]
6. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer.
Stephan C; Yousef GM; Scorilas A; Jung K; Jung M; Kristiansen G; Hauptmann S; Kishi T; Nakamura T; Loening SA; Diamandis EP
J Urol; 2004 Jan; 171(1):187-91. PubMed ID: 14665873
[TBL] [Abstract][Full Text] [Related]
7. Expression and role of Foxa proteins in prostate cancer.
Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma.
Fixemer T; Remberger K; Bonkhoff H
Prostate; 2003 Feb; 54(2):79-87. PubMed ID: 12497580
[TBL] [Abstract][Full Text] [Related]
9. Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
Xuan JA; Schneider D; Toy P; Lin R; Newton A; Zhu Y; Finster S; Vogel D; Mintzer B; Dinter H; Light D; Parry R; Polokoff M; Whitlow M; Wu Q; Parry G
Cancer Res; 2006 Apr; 66(7):3611-9. PubMed ID: 16585186
[TBL] [Abstract][Full Text] [Related]
10. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
Saleem M; Adhami VM; Zhong W; Longley BJ; Lin CY; Dickson RB; Reagan-Shaw S; Jarrard DF; Mukhtar H
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):217-27. PubMed ID: 16492908
[TBL] [Abstract][Full Text] [Related]
11. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
12. Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues.
Vaarala MH; Porvari KS; Kellokumpu S; Kyllönen AP; Vihko PT
J Pathol; 2001 Jan; 193(1):134-40. PubMed ID: 11169526
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.
Hermans KG; Boormans JL; Gasi D; van Leenders GJ; Jenster G; Verhagen PC; Trapman J
Clin Cancer Res; 2009 Oct; 15(20):6398-403. PubMed ID: 19825963
[TBL] [Abstract][Full Text] [Related]
14. High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8.
Tanaka A; Furuya A; Yamasaki M; Hanai N; Kuriki K; Kamiakito T; Kobayashi Y; Yoshida H; Koike M; Fukayama M
Cancer Res; 1998 May; 58(10):2053-6. PubMed ID: 9605740
[TBL] [Abstract][Full Text] [Related]
15. Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer.
Ho LL; Kench JG; Handelsman DJ; Scheffer GL; Stricker PD; Grygiel JG; Sutherland RL; Henshall SM; Allen JD; Horvath LG
Prostate; 2008 Sep; 68(13):1421-9. PubMed ID: 18615486
[TBL] [Abstract][Full Text] [Related]
16. Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors.
Halin S; Wikström P; Rudolfsson SH; Stattin P; Doll JA; Crawford SE; Bergh A
Cancer Res; 2004 Aug; 64(16):5664-71. PubMed ID: 15313905
[TBL] [Abstract][Full Text] [Related]
17. Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium.
Long H; Crean CD; Lee WH; Cummings OW; Gabig TG
Cancer Res; 2001 Nov; 61(21):7878-81. PubMed ID: 11691807
[TBL] [Abstract][Full Text] [Related]
18. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts.
Galkin AV; Mullen L; Fox WD; Brown J; Duncan D; Moreno O; Madison EL; Agus DB
Prostate; 2004 Nov; 61(3):228-35. PubMed ID: 15368474
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic analysis of mice lacking the Tmprss2-encoded protease.
Kim TS; Heinlein C; Hackman RC; Nelson PS
Mol Cell Biol; 2006 Feb; 26(3):965-75. PubMed ID: 16428450
[TBL] [Abstract][Full Text] [Related]
20. Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma.
Uhland K; Siphos B; Arkona C; Schuster M; Petri B; Steinmetzer P; Mueller F; Schweinitz A; Steinmetzer T; Van De Locht A
Int J Oncol; 2009 Aug; 35(2):347-57. PubMed ID: 19578749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
